## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($302.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Assessing Amgen (AMGN)’s Valuation After FDA Approval of Uplizna for Generalized Myasthenia Gravis**
- Source: Simply Wall Street | 20251213T140721 | Bullish | Relevance: 100%
- Amgen (AMGN) recently secured FDA approval for Uplizna, its CD19 targeted B cell therapy for generalized myasthenia gravis, leading to a reassessment of its valuation. Despite strong year-to-date share price performance and a recent dividend increase, the article asks if Amgen is undervalued given its expanding rare disease portfolio or if future growth is already priced in. A narrative valuation suggests the stock is modestly undervalued with a fair value of $322.88 based on projected revenues and earnings by 2028.

**2. Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet**
- Source: Citeline News & Insights | 20251212T230742 | Bullish | Relevance: 100%
- Amgen's Uplizna has received approval for generalized myasthenia gravis, marking its third and most competitive indication. This approval follows earlier indications for IgG4 disease and is expected to further boost sales. The company anticipates Uplizna becoming a new standard of care in the treatment of myasthenia gravis.

**3. FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease**
- Source: Yahoo Finance | 20251212T174449 | Bullish | Relevance: 100%
- The FDA has approved Amgen's UPLIZNA® (inebilizumab-cdon) for generalized myasthenia gravis (gMG) in specific adult patients, marking it as the first and only CD19-targeted B-cell therapy for this condition. This approval provides a new treatment option that promises long-term disease control with just two doses a year after initial loading doses, building on its proven track record in other immune-mediated disorders. The Muscular Dystrophy Association (MDA) recognizes this as a significant step forward, expanding therapeutic choices and offering renewed hope for gMG patients.

**4. Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG**
- Source: Stock Titan | 20251211T231111 | Bullish | Relevance: 100%
- Amgen (NASDAQ:AMGN) announced FDA approval of UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-AChR and anti-MuSK antibody positive. This approval is based on data from the Phase 3 MINT trial, demonstrating significant symptom control and marking UPLIZNA as the first CD19-targeted B-cell therapy for these gMG subtypes, with a convenient twice-yearly maintenance dosing schedule. UPLIZNA already has two previous FDA approvals for NMOSD and IgG4-RD, establishing it as a multi-indication therapy.

**5. Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52**
- Source: MarketBeat | 20251210T160444 | Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ:AMGN) has announced a quarterly dividend of $2.52 per share, representing a 5.9% increase from its previous dividend. The company boasts a strong track record of dividend increases for 14 consecutive years with a sustainable payout ratio of 44.2%, supported by analysts' projected earnings per share of $21.39 for the next year. Amgen's recent earnings exceeded expectations, further solidifying its financial position.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Forward P/E 14.5x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $171.1B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 14.5 |
| Current P/E | 15.0 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.8% to -1.9% (+3.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-4.36), momentum weakening. RSI neutral at 43. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.86% (CS: 12) | Neutral |
| RSI_14 | 43.3 | Neutral |
| MACD Histogram | -4.36 | Bearish |
| vs SMA20 | 0.951x | Below |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.070x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $317.74
- **Stop Loss:** $302.58 (4.8% risk)
- **Target:** $332.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $20,653.10
- **Portfolio %:** 20.65%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*